Zobrazeno 1 - 10
of 102
pro vyhledávání: '"Hong Yun Zhao"'
Autor:
Xiao-Li Wei, Fu-Rong Liu, Ji-Hong Liu, Hong-Yun Zhao, Yang Zhang, Zhi-Qiang Wang, Miao-Zhen Qiu, Fei Xu, Qiu-Qiong Yu, Yi-Wu Du, Yan-Xia Shi, De-Sheng Wang, Feng-Hua Wang, Rui-Hua Xu
Publikováno v:
Nature Communications, Vol 13, Iss 1, Pp 1-10 (2022)
PIK3CA is a commonly mutated cancer-associated gene, making it an attractive therapeutic target. Here, the authors report the results of a first-in-human phase Ia trial to assess the safety and recommended phase II dose of CYH33, a PI3Kα inhibitor,
Externí odkaz:
https://doaj.org/article/e1f16c3559294902ac1b66c1f48464a7
Autor:
Fan Luo, Kang-mei Zeng, Jia-xin Cao, Ting Zhou, Su-xia Lin, Wen-juan Ma, Yun-peng Yang, Zhong-han Zhang, Fei-teng Lu, Yan Huang, Hong-yun Zhao, Li Zhang
Publikováno v:
Lipids in Health and Disease, Vol 20, Iss 1, Pp 1-14 (2021)
Abstract Background Cancer patients often exhibit chemotherapy-associated changes in serum lipid profiles, however, their prognostic value before and after adjuvant chemotherapy on survival among non-small-cell lung cancer (NSCLC) patients is unknown
Externí odkaz:
https://doaj.org/article/daae78ede35d4890bd30b6991daf3401
Autor:
Fan Luo, Fei-Teng Lu, Miao-Zhen Qiu, Ting Zhou, Wen-Juan Ma, Min Luo, Kang-Mei Zeng, Qiu-Yun Luo, Wen-Tao Pan, Lin Zhang, Zeng-Fei Xia, Zhong-Han Zhang, Jia-Xin Cao, Hong-Yun Zhao, Li Zhang, Da-Jun Yang
Publikováno v:
Cell Death and Disease, Vol 12, Iss 8, Pp 1-14 (2021)
Abstract Advanced nasopharyngeal carcinoma (NPC) has a poor prognosis, with an unfavorable response to palliative chemotherapy. Unfortunately, there are few effective therapeutic regimens. Therefore, we require novel treatment strategies with enhance
Externí odkaz:
https://doaj.org/article/c8fd1d13c348483b94e5ed6a0209e578
Autor:
Yu-Xiang Ma, Fu-Rong Liu, Yang Zhang, Qun Chen, Zhi-Qiang Chen, Qian-Wen Liu, Yan Huang, Yun-Peng Yang, Wen-Feng Fang, Ning Xi, Ning Kang, Yu-Lei Zhuang, Qi Zhang, Ying-Zhi Jiang, Li Zhang, Hong-Yun Zhao
Publikováno v:
Frontiers in Immunology, Vol 13 (2022)
BackgroundCT053PTSA is a novel tyrosine kinase inhibitor that targets MET, AXL, VEGFR2, FLT3 and MERTK. Here, we present preclinical data about CT053PTSA, and we conducted the first-in-human (FIH) study to evaluate the use of CT053PTSA in adult patie
Externí odkaz:
https://doaj.org/article/9203def0acce4b9996448bf4531c81d0
Autor:
Xiao‐Li Wei, Chao Ren, Feng‐Hua Wang, Yang Zhang, Hong‐Yun Zhao, Ben‐Yan Zou, Zhi‐Qiang Wang, Miao‐Zhen Qiu, Dong‐Sheng Zhang, Hui‐Yan Luo, Feng Wang, Sheng Yao, Rui‐Hua Xu
Publikováno v:
Cancer Communications, Vol 40, Iss 8, Pp 345-354 (2020)
Abstract Background Several programmed cell death ligand 1 (PD‐L1)/programmed cell death protein 1 (PD‐1) antibodies have been approved for cancer treatment worldwide. Their pharmacokinetic and pharmacodynamic characteristics have been reported m
Externí odkaz:
https://doaj.org/article/8ce01e25a806447a911986d71c98652a
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-13 (2019)
Abstract Background PD-1/PD-L1 blockade has received approval for clinical application due to its encouraging benefit with improving prognosis in selected populations. Unfortunately, the response to immunotherapy for many patients remains unsatisfact
Externí odkaz:
https://doaj.org/article/61e618e90cc54e2882cf13879d991855
Autor:
Fan Luo, Kang‐mei Zeng, Zhong‐han Zhang, Ting Zhou, Jian‐hua Zhan, Fei‐teng Lu, Yun‐peng Yang, Yan Huang, Li Zhang, Hong‐yun Zhao
Publikováno v:
Clinical and Translational Medicine, Vol 10, Iss 2, Pp n/a-n/a (2020)
Externí odkaz:
https://doaj.org/article/8577054f452d4d90882f6f50557582eb
Autor:
Yun-Feng Liang, Francesca Alemanno, Qi An, Philipp Azzarello, Felicia Carla Tiziana Barbato, Paolo Bernardini, Xiao-Jun Bi, Ming-Sheng Cai, Elisabetta Casilli, Enrico Catanzani, Jin Chang, Deng-Yi Chen, Jun-Ling Chen, Zhan-Fang Chen, Ming-Yang Cui, Tian-Shu Cui, Yu-Xing Cui, Hao-Ting Dai, Antonio De Benedittis, Ivan De Mitri, Francesco de Palma, Maksym Deliyergiyev, Margherita Di Santo, Qi Ding, Tie-Kuang Dong, Zhen-Xing Dong, Giacinto Donvito, David Droz, Jing-Lai Duan, Kai-Kai Duan, Domenico D’Urso, Rui-Rui Fan, Yi-Zhong Fan, Fang Fang, Kun Fang, Chang-Qing Feng, Lei Feng, Piergiorgio Fusco, Min Gao, Fabio Gargano, Ke Gong, Yi-Zhong Gong, Dong-Ya Guo, Jian-Hua Guo, Shuang-Xue Han, Yi-Ming Hu, Guang-Shun Huang, Xiao-Yuan Huang, Yong-Yi Huang, Maria Ionica, Wei Jiang, Jie Kong, Andrii Kotenko, Dimitrios Kyratzis, Shi-Jun Lei, Shang Li, Wen-Hao Li, Wei-Liang Li, Xiang Li, Xian-Qiang Li, Yao-Ming Liang, Cheng-Ming Liu, Hao Liu, Jie Liu, Shu-Bin Liu, Yang Liu, Francesco Loparco, Chuan-Ning Luo, Miao Ma, Peng-Xiong Ma, Tao Ma, Xiao-Yong Ma, Giovanni Marsella, Mario Nicola Mazziotta, Dan Mo, Maria Muñoz Salinas, Xiao-Yang Niu, Xu Pan, Andrea Parenti, Wen-Xi Peng, Xiao-Yan Peng, Chiara Perrina, Rui Qiao, Jia-Ning Rao, Arshia Ruina, Zhi Shangguan, Wei-Hua Shen, Zhao-Qiang Shen, Zhong-Tao Shen, Leandro Silveri, Jing-Xing Song, Mikhail Stolpovskiy, Hong Su, Meng Su, Hao-Ran Sun, Zhi-Yu Sun, Antonio Surdo, Xue-Jian Teng, Andrii Tykhonov, Jin-Zhou Wang, Lian-Guo Wang, Shen Wang, Shu-Xin Wang, Xiao-Lian Wang, Ying Wang, Yan-Fang Wang, Yuan-Zhu Wang, Da-Ming Wei, Jia-Ju Wei, Yi-Feng Wei, Di Wu, Jian Wu, Li-Bo Wu, Sha-Sha Wu, Xin Wu, Zi-Qing Xia, En-Heng Xu, Hai-Tao Xu, Zhi-Hui Xu, Zun-Lei Xu, Zi-Zong Xu, Guo-Feng Xue, Hai-Bo Yang, Peng Yang, Ya-Qing Yang, Hui-Jun Yao, Yu-Hong Yu, Guan-Wen Yuan, Qiang Yuan, Chuan Yue, Jing-Jing Zang, Sheng-Xia Zhang, Wen-Zhang Zhang, Yan Zhang, Yi Zhang, Yong-Jie Zhang, Yun-Long Zhang, Ya-Peng Zhang, Yong-Qiang Zhang, Zhe Zhang, Zhi-Yong Zhang, Cong Zhao, Hong-Yun Zhao, Xun-Feng Zhao, Chang-Yi Zhou, Yan Zhu
Publikováno v:
Science Bulletin. 67:679-684
The DArk Matter Particle Explorer (DAMPE) is well suitable for searching for monochromatic and sharp $\gamma$-ray structures in the GeV$-$TeV range thanks to its unprecedented high energy resolution. In this work, we search for $\gamma$-ray line stru
Autor:
Li-wu Fu, Zhe-Sheng Chen, Suresh V. Ambudkar, Kenneth Kin Wah To, Xiao-xu Ma, Amit K. Tiwari, Chun-Ling Dai, Chuan-zhao Zhang, Li-yang Tao, Fang Wang, Chung-Pu Wu, Hong-yun Zhao, Hong-bing Huang, Yong-ju Liang, Yan-jun Mi
Apatinib, a small-molecule multitargeted tyrosine kinase inhibitor, is in phase III clinical trial for the treatment of patients with non–small-cell lung cancer and gastric cancer in China. In this study, we determined the effect of apatinib on the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0a074bd4e29f4a730f9d8a02e224c6c5
https://doi.org/10.1158/0008-5472.c.6500690
https://doi.org/10.1158/0008-5472.c.6500690
Autor:
Li-wu Fu, Zhe-Sheng Chen, Suresh V. Ambudkar, Kenneth Kin Wah To, Xiao-xu Ma, Amit K. Tiwari, Chun-Ling Dai, Chuan-zhao Zhang, Li-yang Tao, Fang Wang, Chung-Pu Wu, Hong-yun Zhao, Hong-bing Huang, Yong-ju Liang, Yan-jun Mi
Supplementary Figure 2 from Apatinib (YN968D1) Reverses Multidrug Resistance by Inhibiting the Efflux Function of Multiple ATP-Binding Cassette Transporters
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2f66ca547ce7543553bfe6c5a8d4142e
https://doi.org/10.1158/0008-5472.22383878
https://doi.org/10.1158/0008-5472.22383878